HeartBeam Inc. (NASDAQ: BEAT) Validates ECG Technology with Strong Results in Pivotal Study
HeartBeam is developing a portable, credit-card-sized device and proprietary software capable of capturing heart signals in three non-coplanar dimensions and reconstructing those signals into a full synthesized 12-lead ECG. The importance of such innovation is underscored by the widespread impact of heart disease, such as heart rhythm problems. The VALID-ECG study results carry significant weight for both clinical adoption and HeartBeam’s commercialization pathway. Early and accurate detection of heart rhythm problems can mean the difference between life-saving intervention and a missed opportunity, which is why new advances in cardiac diagnostics carry such weight. HeartBeam (NASDAQ: BEAT) has reported promising results…